Tuesday, September 19, 2017 9:15:07 PM
Peregrine and Epiontis
Epiontis has Ulrich Hoffmueller with #1 collaborator Sven Olek
https://www.researchgate.net/profile/Ulrich_Hoffmueller
I still insist that patents that are filed as a result of collaborations with PS Targeting and learning new facts, new knowledge .....that IS NOT common knowledge ..etc etc may have to give some rights back to Peregrine and I hope Peregrine can see whom they gave PS Targeting info to and patents filed soon after must be monitored ...and questioned how such info would be known if it were not for PS Targeting knowledge and seeing which BIOMARKERS to concentrate on...etc
I am not saying this patent below falls into this but interesting filed April and published soon after....
_____________________
Epigenetic Markers for the Identification of Blood Sub-cells of Type 1
Publication number: 20170233807
Abstract: The present invention relates to a method, in particular an in vitro method, for identifying CD3CD4 positive T lymphocytes of a mammal, wherein said method comprises analysing the methylation status of at least one CpG position in the CD3a/b/c/d/g genes, in particular their “upstream” regulatory regions, and in particular the promoter and other conserved regions of the gene cd3, wherein a demethylation of at least one CpG in the analyzed sample to at least 90% is indicative for memory and naive CD4 or/and memory and/or naïve T lymphocytes. Furthermore, the present invention is directed at the use of DNA-methylation analysis of the genes CD3a/b/c/d for the detection and quality assurance and control of T lymphocytes. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses thereof.
Type: Application
Filed: April 3, 2017
Publication date: August 17, 2017
Inventors: Sven OLEK, Ivana TÜRBACHOVA - deceased
http://patents.justia.com/inventor/sven-olek
____________
Ivana passed.....though one can see she was longtime researcher on patents with Sven Olek ....even back in 2005 era
https://www.google.com/patents/WO2006094836A3?cl=zh:
http://patents.justia.com/inventor/ivana-t-rbachova
__________
Paul Gardina also on those patents with Ivana and Sven, back in 2905 above and co-founder Epiontis
Background
Dr. Paul Gardina is currently employed at Epiontis GmbH in the position of CSO/CIO. He is also a Co-founder of the company. He has a B.S. in Biochemistry and Ph.D. in Molecular Biology from Texas A&M University (TX, USA). Bioinformatic Scientist at LION Bioscience in Heidelberg, Germany and Boston, MA, USA, primarily in metabolic databases, software development and genome annotation.
http://www.bloomberg.com/research/stocks/private/person.asp?personId=6281608&privcapId=6280837&previousCapId=6280837&previousTitle=Epiontis%20GmbH
_____________
https://www.ncbi.nlm.nih.gov/pubmed/28691938
https://www.ncbi.nlm.nih.gov/pubmed/12050117
http://www.abstammungsbegutachtung.de/EN-Labor%20f%FCr%20Abstammungsbegutachtungen%20Web-Site/PARENTAGE-PATERNITY%20ANALYSIS/gutachten.html
Epiontis has Ulrich Hoffmueller with #1 collaborator Sven Olek
https://www.researchgate.net/profile/Ulrich_Hoffmueller
I still insist that patents that are filed as a result of collaborations with PS Targeting and learning new facts, new knowledge .....that IS NOT common knowledge ..etc etc may have to give some rights back to Peregrine and I hope Peregrine can see whom they gave PS Targeting info to and patents filed soon after must be monitored ...and questioned how such info would be known if it were not for PS Targeting knowledge and seeing which BIOMARKERS to concentrate on...etc
I am not saying this patent below falls into this but interesting filed April and published soon after....
_____________________
Epigenetic Markers for the Identification of Blood Sub-cells of Type 1
Publication number: 20170233807
Abstract: The present invention relates to a method, in particular an in vitro method, for identifying CD3CD4 positive T lymphocytes of a mammal, wherein said method comprises analysing the methylation status of at least one CpG position in the CD3a/b/c/d/g genes, in particular their “upstream” regulatory regions, and in particular the promoter and other conserved regions of the gene cd3, wherein a demethylation of at least one CpG in the analyzed sample to at least 90% is indicative for memory and naive CD4 or/and memory and/or naïve T lymphocytes. Furthermore, the present invention is directed at the use of DNA-methylation analysis of the genes CD3a/b/c/d for the detection and quality assurance and control of T lymphocytes. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses thereof.
Type: Application
Filed: April 3, 2017
Publication date: August 17, 2017
Inventors: Sven OLEK, Ivana TÜRBACHOVA - deceased
http://patents.justia.com/inventor/sven-olek
____________
Ivana passed.....though one can see she was longtime researcher on patents with Sven Olek ....even back in 2005 era
https://www.google.com/patents/WO2006094836A3?cl=zh:
http://patents.justia.com/inventor/ivana-t-rbachova
__________
Paul Gardina also on those patents with Ivana and Sven, back in 2905 above and co-founder Epiontis
Background
Dr. Paul Gardina is currently employed at Epiontis GmbH in the position of CSO/CIO. He is also a Co-founder of the company. He has a B.S. in Biochemistry and Ph.D. in Molecular Biology from Texas A&M University (TX, USA). Bioinformatic Scientist at LION Bioscience in Heidelberg, Germany and Boston, MA, USA, primarily in metabolic databases, software development and genome annotation.
http://www.bloomberg.com/research/stocks/private/person.asp?personId=6281608&privcapId=6280837&previousCapId=6280837&previousTitle=Epiontis%20GmbH
_____________
https://www.ncbi.nlm.nih.gov/pubmed/28691938
https://www.ncbi.nlm.nih.gov/pubmed/12050117
http://www.abstammungsbegutachtung.de/EN-Labor%20f%FCr%20Abstammungsbegutachtungen%20Web-Site/PARENTAGE-PATERNITY%20ANALYSIS/gutachten.html
